Krishna Institute of Medical Sciences approves unaudited Q1 consolidated results
Krishna Institute of Medical Sciences · Healthcare Services
Key highlights
- Consolidated revenue from operations Rs 11,795 million and profit for the period Rs 374 million for quarter ended 30 June 2026
- Issued 19,867,549 equity shares via QIP at Rs 755 per share, aggregating Rs 15,000 million; issue expenses Rs 237 million
- Board approved up to 7,702,182 convertible warrants at Rs 779 per warrant, aggregating up to Rs 6,000 million, on preferential basis to promoters; board approval dated 13 June 2026
Why it's rated major development: the year-on-year change is 47% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Financial Results For Q1 2026-27
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Krishna Institute of Medical Sciences
- Financial resultsNotableKrishna Institute of Medical Sciences Ltd announces Q2 results and key appointments
- Acquisition / mergerNotableKrishna Institute of Medical Sciences approves Q2 financials and key reappointments
- Acquisition / mergerNotableKIMS announces acquisition of up to 51% stake in Insignia Healthcare Pvt Ltd
- Fundraise / allotmentNotableKrishna Institute of Medical Sciences receives NSE and BSE in-principle approval for warrant issue
- Fundraise / allotmentNotableKrishna Institute of Medical Sciences closes qualified institutions placement issue on June 19, 2026
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.